Endozepine-4 levels are increased in hepatic coma.

Area of Science:

• Hepatology
• Neuroscience
• Biochemistry

Background:

• Hepatic encephalopathy (HE) is a complex neuropsychiatric complication of liver dysfunction.
• The role of specific neuroactive substances, such as endozepines, in HE pathogenesis requires further elucidation.
• Endozepine-4, a neurosteroid, is implicated in GABAergic neurotransmission, which is often altered in HE.

Purpose of the Study:

• To investigate serum endozepine-4 levels in patients with varying degrees of hepatic encephalopathy.
• To assess the correlation between endozepine-4, ammonia levels, and the severity of liver disease (cirrhosis grading, MELD score).
• To explore the relationship between endozepine-4 and the grade of coma in hepatic patients.

Main Methods:

• Cross-sectional study involving 60 participants: 20 with hepatic coma, 20 with minimal hepatic encephalopathy (MHE), and 20 healthy controls.
• Blood samples were analyzed for endozepine-4 and ammonia (NH3) levels.
• Clinical assessments included grading of coma, Child-Pugh score, and Model for End-Stage Liver Disease (MELD) score.

Main Results:

• Serum endozepine-4 and ammonia levels were significantly elevated in patients with hepatic coma compared to MHE and control groups (P < 0.001).
• A significant positive correlation was observed between endozepine-4 and ammonia levels (r = 0.570, P = 0.009).
• Endozepine-4 levels also correlated significantly with MELD scores (r = 0.529, P = 0.017), and were highest in patients with Grade IV hepatic coma.

Conclusions:

• Increased serum endozepine-4 levels are associated with higher MELD scores and more severe hepatic encephalopathy.
• The findings suggest stage-specific alterations in the GABA-ergic system contribute to the neurobiology of hepatic coma.
• Endozepine-4 may serve as a potential biomarker for HE severity and liver disease progression.